Aurealis Therapeutics accelerates oncology program: First abstract published at ASCO as the team prepares for Annual Meeting in Chicago
Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for unmet medical needs, accelerates its expansion in Oncology with its first-in-class four-in-one Bacterial Cell and Gene Therapy AUP-55. The company’s first abstract, Effect of multi-targeting bacterial gene therapy on tumor regression and survival in mouse models of ovarian and intraperitoneal cancer, has […]
